An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells.
HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface.
Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured.
Metastatic cancer is the type where the cancer cells spread from one part of the body to another.
This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy.
Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins.
PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle.
The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.
Inclusion Criteria:
Exclusion Criteria:
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Camarillo, California 93010, United States
Glendale, California 91204, United States
Los Angeles, California 90017, United States
Los Angeles, California 90017, United States
Oxnard, California 93030, United States
Oxnard, California 93036, United States
Ventura, California 93003, United States
Washington D.C., District of Columbia 20010, United States
Germantown, Tennessee 38138, United States
Mechanicsville, Virginia 23116, United States
Brussels, Bruxelles-capitale, Région de 1200, Belgium
Vitória, Espírito Santo 29043-260, Brazil
Ijuí, Rio Grande do Sul 98700-000, Brazil
Sofia, Sofia (stolitsa) 1632, Bulgaria
Wuhan, Hubei 430030, China
Nanjing, Jiangsu 210031, China
Rennes, Brittany Region 35042, France
Vandœuvre-lès-Nancy, Lorraine 54519, France
Haifa, Northern District 3109601, Israel
Bologna, Emilia-Romagna 40138, Italy
Meldola, Emilia-Romagna 47014, Italy
Naples, Naples 80131, Italy
Otashi, Gunma 373-8550, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
Krakow, Lesser Poland Voivodeship 30-348, Poland
Gangnam-gu, Seoul-teukbyeolsi [seoul] 06273, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
A Coruña, A Coruña [LA Coruña] 15006, Spain